Trial Profile
A randomised phase II study comparing cisplatin and docetaxel with or without cetuximab given as neoadjuvant therapy in patients with stage II and IIIA resectable non-small cell lung cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jun 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ANTS
- 08 Jun 2016 Status changed from not yet recruiting to completed.
- 14 May 2009 New trial record